SCYNEXIS (SCYX) CEO joins private placement, adds stock and warrants

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

SCYNEXIS INC Chief Executive Officer David Angulo Gonzalez purchased additional equity through a private placement. On March 30, 2026, he agreed to buy 108,695 shares of common stock and accompanying warrants to purchase up to 108,695 shares, which closed on April 1, 2026, at a combined purchase price of $0.92 per share and warrant unit. The new Common Warrants will become exercisable once stockholders approve an increase in authorized common shares and will expire on the earlier of five years from issuance or 30 days after SCYNEXIS releases Week 48 topline data from its Phase 2 proof-of-concept clinical study of SCY-770 in autosomal dominant polycystic kidney disease. Following these transactions, he directly owns 1,357,126 shares of common stock, including 4,000 acquired under the 2014 Employee Stock Purchase Plan.

Insider Trade Summary

2 transactions reported

Net Buy 2 txns

Insider Angulo Gonzalez David

Role Chief Executive Officer

Bought 217,390 shs ($0.00)

Type	Security	Shares	Price	Value
Purchase	Warrant to Purchase Common Stock	108,695	$0.00	--
Purchase	Common Stock	108,695	$0.00	--

Holdings After Transaction: Warrant to Purchase Common Stock — 108,695 shares (Direct); Common Stock — 1,357,126 shares (Direct)

Footnotes (1)

On March 30, 2026, the Issuer entered into a Securities Purchase Agreement with certain accredited investors, including the Reporting Person (the "Purchase Agreement"). Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on April 1, 2026, 108,695 shares of the Issuer's common stock (the "Shares") and accompanying warrants to purchase up to 108,695 shares of common stock of the Issuer (the "Common Warrants"). The combined purchase price for each Share and accompanying Common Warrant was $0.92. Includes 4,000 shares of common stock acquired under the 2014 Employee Stock Purchase Plan of the Issuer on March 5, 2026. The Common Warrants will be exercisable beginning on the effective date of the stockholder approval relating to the proposed increase in the Issuer's authorized shares of common stock. The Common Warrants will expire on the earlier of (i) the fifth (5th) anniversary of its original issue date and (ii) the thirtieth (30th) day after the Issuer publicly releases topline data at Week 48 from the Issuer's Phase 2 proof-ofconcept clinical study evaluating SCY-770 in patients with autosomal dominant polycystic kidney disease.

Key Figures

Common shares purchased: 108,695 shares Warrants acquired: 108,695 warrants Combined purchase price: $0.92 per share and warrant unit +2 more

5 metrics

Common shares purchased 108,695 shares Private placement closed April 1, 2026

Warrants acquired 108,695 warrants Accompanying warrants to purchase common stock

Combined purchase price $0.92 per share and warrant unit Securities Purchase Agreement dated March 30, 2026

Shares owned after transaction 1,357,126 shares Total direct common stock holdings after April 1, 2026

ESPP shares included 4,000 shares Acquired under 2014 Employee Stock Purchase Plan on March 5, 2026

Key Terms

Securities Purchase Agreement, private placement, Common Warrants, Employee Stock Purchase Plan, +1 more

5 terms

Securities Purchase Agreement financial

"the Issuer entered into a Securities Purchase Agreement with certain accredited investors"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

private placement financial

"issued and sold to the Reporting Person in a private placement, which closed on April 1, 2026"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

Common Warrants financial

"accompanying warrants to purchase up to 108,695 shares of common stock of the Issuer (the "Common Warrants")"

A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.

Employee Stock Purchase Plan financial

"Includes 4,000 shares of common stock acquired under the 2014 Employee Stock Purchase Plan of the Issuer"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Phase 2 proof-of-concept clinical study medical

"Phase 2 proof-ofconcept clinical study evaluating SCY-770 in patients with autosomal dominant polycystic kidney disease"

Form 4 Insider Transactions: What Each Field Means →

04/02/2026 - 08:01 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Angulo Gonzalez David

(Last)

(First)

(Middle)

1 EVERTRUST PLAZA

13TH FLOOR

(Street)

JERSEY CITY

NEW JERSEY

07302

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SCYNEXIS INC [ SCYX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/01/2026		P		108,695	A	⁽¹⁾	1,357,126⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrant to Purchase Common Stock	$1.2	04/01/2026		P		108,695		⁽³⁾	⁽⁴⁾	Common Stock	108,695	⁽¹⁾	108,695	D

Explanation of Responses:

1. On March 30, 2026, the Issuer entered into a Securities Purchase Agreement with certain accredited investors, including the Reporting Person (the "Purchase Agreement"). Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on April 1, 2026, 108,695 shares of the Issuer's common stock (the "Shares") and accompanying warrants to purchase up to 108,695 shares of common stock of the Issuer (the "Common Warrants"). The combined purchase price for each Share and accompanying Common Warrant was $0.92.

2. Includes 4,000 shares of common stock acquired under the 2014 Employee Stock Purchase Plan of the Issuer on March 5, 2026.

3. The Common Warrants will be exercisable beginning on the effective date of the stockholder approval relating to the proposed increase in the Issuer's authorized shares of common stock.

4. The Common Warrants will expire on the earlier of (i) the fifth (5th) anniversary of its original issue date and (ii) the thirtieth (30th) day after the Issuer publicly releases topline data at Week 48 from the Issuer's Phase 2 proof-ofconcept clinical study evaluating SCY-770 in patients with autosomal dominant polycystic kidney disease.

	/s/ Robert F. Joyce Jr., by Power of Attorney	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did SCYNEXIS (SCYX) CEO David Angulo Gonzalez purchase in this Form 4?

He purchased 108,695 shares of SCYNEXIS common stock and accompanying warrants to buy up to 108,695 additional shares. The transaction was part of a private placement with accredited investors that closed on April 1, 2026, at a combined price of $0.92 per share and warrant unit.

What is the purchase price disclosed for the SCYNEXIS (SCYX) CEO’s new shares and warrants?

The combined purchase price was $0.92 for each share of common stock plus its accompanying warrant. This price applied within a private placement under a Securities Purchase Agreement signed on March 30, 2026, and closed on April 1, 2026, with accredited investors including the CEO.

When can the new SCYNEXIS (SCYX) Common Warrants held by the CEO be exercised?

The Common Warrants will be exercisable beginning on the effective date of stockholder approval for a proposed increase in authorized common shares. This means the warrants cannot be exercised until shareholders approve that increase and it becomes effective, according to the described terms.

When do the SCYNEXIS (SCYX) CEO’s newly acquired Common Warrants expire?

The Common Warrants expire on the earlier of five years from their original issue date or 30 days after SCYNEXIS publicly releases Week 48 topline data from its Phase 2 proof-of-concept study of SCY-770 in autosomal dominant polycystic kidney disease, whichever occurs first under the warrant terms.

How many SCYNEXIS (SCYX) shares does the CEO own after this Form 4 transaction?

After the transaction, the CEO directly holds 1,357,126 shares of SCYNEXIS common stock. This total includes 4,000 shares previously acquired on March 5, 2026, under the company’s 2014 Employee Stock Purchase Plan, as referenced in the filing’s footnotes.

How is the SCYNEXIS (SCYX) CEO’s participation in the private placement described?

He participated as an accredited investor under a Securities Purchase Agreement dated March 30, 2026. The issuer sold him 108,695 shares of common stock and matching warrants in a private placement that closed April 1, 2026, aligning his purchase terms with those of other accredited investors.

SCYNEXIS (SCYX) CEO joins private placement, adds stock and warrants

Rhea-AI Filing Summary

Positive